Kiniksa Pharmaceuticals International (NAS:KNSA) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Kiniksa Pharmaceuticals International PS Ratio Related Terms
Kiniksa Pharmaceuticals International PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiniksa Pharmaceuticals International PS Ratio Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Kiniksa Pharmaceuticals International's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kiniksa Pharmaceuticals International PS Ratio vs Drug Manufacturers Industry
Kiniksa Pharmaceuticals International PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Kiniksa Pharmaceuticals International's Share Price of today is $64.53. Kiniksa Pharmaceuticals International's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.34.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Kiniksa Pharmaceuticals International (KNSA) has a PS Ratio of 6.91 as of Jul. 04, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Kiniksa Pharmaceuticals International and its competitors. This is 37% above median its historical median of 5.04. Over the past decade, Kiniksa Pharmaceuticals International's PS Ratio has ranged from 2.93 to 135.66. According to the industry distribution chart, Kiniksa Pharmaceuticals International ranks #760 out of 950 companies in the Drug Manufacturers industry, placing it in the top 80%.
Is Kiniksa Pharmaceuticals International's PS Ratio too high?
Kiniksa Pharmaceuticals International's current PS Ratio of 6.91 is 37% above median its 10-year median of 5.04. Over the past 10 years, this metric has ranged from a low of 2.93 to a high of 135.66. The Drug Manufacturers industry median PS Ratio is 2.32. Kiniksa Pharmaceuticals International's value of 6.91 is 198.5% above this industry median. Based on the distribution chart, Kiniksa Pharmaceuticals International ranks #760 out of 950 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Kiniksa Pharmaceuticals International has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kiniksa Pharmaceuticals International's PS Ratio compare to INDV and AMRX?
According to the Drug Manufacturers industry distribution chart, Kiniksa Pharmaceuticals International ranks #760 out of 950 companies for PS Ratio. This places Kiniksa Pharmaceuticals International in the lower half of its industry. The industry median PS Ratio is 2.32. Kiniksa Pharmaceuticals International's value of 6.91 is 198.5% above this benchmark. Historically, Kiniksa Pharmaceuticals International's own PS Ratio has ranged from 2.93 to 135.66 over the past decade. While the company's 10-year median is 5.04 vs. the industry median of 2.32, Kiniksa Pharmaceuticals International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.32, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kiniksa Pharmaceuticals International's current PS Ratio of 6.91 is 198.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Kiniksa Pharmaceuticals International and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kiniksa Pharmaceuticals International's current PS Ratio is 6.91, which is 37% above median its own 10-year median of 5.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiniksa Pharmaceuticals International stock overvalued right now?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International (KNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is $48.22, compared to a current price of $64.53 — trading 33.8% above its estimated fair value. The current PS Ratio is 6.91, which is 37% above median its 10-year median of 5.04 and 198.5% above the Drug Manufacturers industry median of 2.32. Kiniksa Pharmaceuticals International's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Kiniksa Pharmaceuticals International (KNSA), the current PS Ratio is 6.91 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kiniksa Pharmaceuticals International (KNSA) Overvalued in 2026?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued.
The current stock price of $64.53 is trading 33.8% above its estimated GF Value™ of $48.22.
GuruFocus considers Kiniksa Pharmaceuticals International to be Significantly Overvalued.
Key valuation signals for KNSA:
PS Ratio: 6.91 (37% above median its 10-year median of 5.04)
GF Value™: $48.22 vs. price of $64.53 (33.8% above fair value)
Industry Position: 198.5% above the Drug Manufacturers median (#760 of 950)
No single metric tells the full story. See the KNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kiniksa Pharmaceuticals International Business Description
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
54GF Score
Get the complete analysis for KNSA
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNSA has been successfully added to your 
